Skip to search formSkip to main contentSkip to account menu

pactimibe sulfate

Known as: CS-505 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

pactimibe

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Intercellular transfer along the trichomes of the invasive terminal heterocyst forming cyanobacterium Cylindrospermopsis raciborskii CS-505.
Cylindrospermopsis raciborskii CS-505 is an invasive freshwater filamentous cyanobacterium that when grown diazotrophically may… 
2013
2013
Dinitrogen Fixation Is Restricted to the Terminal Heterocysts in the Invasive Cyanobacterium Cylindrospermopsis raciborskii CS-505
The toxin producing nitrogen-fixing heterocystous freshwater cyanobacterium Cylindrospermopsis raciborskii recently radiated from… 
2009
2009
Optimization of 2D‐PAGE protocols for proteomic analysis of two nonaxenic toxin‐producing freshwater cyanobacteria: Cylindrospermopsis raciborskii and Raphidiopsis sp.
Aims:  To optimize a protocol for the extraction and an in‐depth analysis of the soluble protein fraction of two nonaxenic toxin… 
2008
2008
Effects of Ketoconazole and Quinidine on Pharmacokinetics of Pactimibe and Its Plasma Metabolite, R-125528, in Humans
Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor developed for the treatment of… 
2008
2008
Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic…
A series of novel indoline derivatives with an ionizable moiety were synthesized to find a bioavailable acyl-CoA:cholesterol… 
2008
2008
Effect of CYP2D6 polymorphism on pharmacokinetics of a novel ACAT inhibitor, pactimibe and its unique metabolite, R-125528.
PURPOSE Pactimibe is a novel ACAT inhibitor. The pharmacokinetics of pactimibe and its pharmacologically inactive plasma… 
Highly Cited
2007
Highly Cited
2007
ACAT inhibitor pactimibe sulfate (CS-505) reduces and stabilizes atherosclerotic lesions by cholesterol-lowering and direct effects in apolipoprotein E-deficient mice.
2006
2006
Th-P16:249 An ACAT1 selective inhibitor, K-604 directly regulates atherosclerotic lesions. A comparison study with the ACAT1/2 non-selective inhibitor CS-505
Review
2001
Review
2001
[Lipid-lowering drugs].
Accumulating evidences in recent major clinical studies have shown the importance of anti-hyperlipidemic treatment in preventing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)